These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34161001)

  • 1. ["Immune checkpoint inhibitors in oncology"].
    Daëron M; Vivier É
    Rev Prat; 2021 Apr; 71(4):374-379. PubMed ID: 34161001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
    Spigel DR; Socinski MA
    J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment.
    Dobosz P; Stępień M; Golke A; Dzieciątkowski T
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for pancreatic cancer: A long and hopeful journey.
    Xu JW; Wang L; Cheng YG; Zhang GY; Hu SY; Zhou B; Zhan HX
    Cancer Lett; 2018 Jul; 425():143-151. PubMed ID: 29605510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
    Laban S; Doescher J; Schuler PJ; Bullinger L; Brunner C; Veit JA; Hoffmann TK
    HNO; 2015 Sep; 63(9):612-9. PubMed ID: 26319429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy comes of age: Immune aging & checkpoint inhibitors.
    Elias R; Karantanos T; Sira E; Hartshorn KL
    J Geriatr Oncol; 2017 May; 8(3):229-235. PubMed ID: 28223073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
    Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
    Joshi M; Pal SK; Drabick JJ
    Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel technologies for applying immune checkpoint blockers.
    Awad RM; Breckpot K
    Int Rev Cell Mol Biol; 2024; 382():1-101. PubMed ID: 38225100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibitors in immunotherapy of ovarian cancer.
    Wang DH; Guo L; Wu XH
    Tumour Biol; 2015 Jan; 36(1):33-9. PubMed ID: 25409618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
    Hussain N; Naeem M; Pinato DJ
    Hum Vaccin Immunother; 2021 Jan; 17(1):55-61. PubMed ID: 32574106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy.
    Li L; Yang Z; Chen X
    Acc Chem Res; 2020 Oct; 53(10):2044-2054. PubMed ID: 32877161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to immune checkpoint inhibitors.
    Jenkins RW; Barbie DA; Flaherty KT
    Br J Cancer; 2018 Jan; 118(1):9-16. PubMed ID: 29319049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way.
    Cunha LL; Marcello MA; Rocha-Santos V; Ward LS
    Endocr Relat Cancer; 2017 Dec; 24(12):T261-T281. PubMed ID: 28893836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy with checkpoint inhibitors in local advanced and metastatic urothelial carcinoma].
    Miller K; Gschwend JE; Merseburger A; Retz M; Stenzl A
    Aktuelle Urol; 2018 Apr; 49(2):142-156. PubMed ID: 29587321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors for Indian patients: A note of caution.
    Venniyoor A
    Indian J Cancer; 2016; 53(3):468-469. PubMed ID: 28244488
    [No Abstract]   [Full Text] [Related]  

  • 19. Managing side effects of immune checkpoint inhibitors in breast cancer.
    Criscitiello C; Corti C; Pravettoni G; Curigliano G
    Crit Rev Oncol Hematol; 2021 Jun; 162():103354. PubMed ID: 34029683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.